HIV-1 Inhibitor 18A
Code | Size | Price |
---|
TAR-T24141-1mg | 1mg | £164.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-1mL | 1 mL * 10 mM (in DMSO) | £254.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-5mg | 5mg | £262.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-10mg | 10mg | £335.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-25mg | 25mg | £523.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-50mg | 50mg | £706.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24141-100mg | 100mg | £970.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
HIV-1 Inhibitor 18A specifically inhibits the entry of multiple HIV-1 isolates.
CAS:
331261-50-8
Formula:
C14H11N5O2S
Molecular Weight:
313.34
Pathway:
Microbiology/Virology; Proteases/Proteasome
Purity:
0.98
SMILES:
Oc1ccc(C=NNC(=O)Nc2cccc3nsnc23)cc1
Target:
HIV Protease
References
1. Berinyuy E, Soliman MES. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling. Interdiscip Sci. 2017 Sep;9(3):406-418. doi: 10.1007/s12539-016-0174-7. Epub 2016 May 10. PubMed PMID: 27165479.
2. Berinyuy E, Soliman ME. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry. J Recept Signal Transduct Res. 2016;36(2):119-29. doi: 10.3109/10799893.2015.1056307. Epub 2015 Oct 8. PubMed PMID: 26446906.
3. Herschhorn A, Gu C, Espy N, Richard J, Finzi A, Sodroski JG. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol. 2014 Oct;10(10):845-52. doi: 10.1038/nchembio.1623. Epub 2014 Aug 31. PubMed PMID: 25174000; PubMed Central PMCID: PMC4231716.
4. Martin SF, Dorsey GO, Gane T, Hillier MC, Kessler H, Baur M, Math? B, Erickson JW, Bhat TN, Munshi S, Gulnik SV, Topol IA. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors. J Med Chem. 1998 May 7;41(10):1581-97. PubMed PMID: 9572884.